MAPT and Alzheimer disease: Multiple studies have demonstrated that plasma p‐tau217 shows strong correlations with both amyloid and tau positron emission tomography (PET) signals and distinguishes AD from other neurodegenerative disorders with high accuracy, outperforming earlier p‐tau isoforms such as p‐tau181 and p‐tau231.1, 2, 3, 4, 5